相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer
Dmitrij Ostroumov et al.
HEPATOLOGY (2021)
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity
Sabine Heitzeneder et al.
CANCER CELL (2021)
PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells
Guodi Liu et al.
HUMAN IMMUNOLOGY (2021)
Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed/refractory acute myeloid leukemia
Guoqiang Lin et al.
MOLECULAR MEDICINE REPORTS (2021)
Counteracting CAR T cell dysfunction
Mansour Poorebrahim et al.
ONCOGENE (2021)
CAR T cells in solid tumors: challenges and opportunities
Faroogh Marofi et al.
STEM CELL RESEARCH & THERAPY (2021)
Deletion of Cbl-b inhibits CD8+ T-cell exhaustion and promotes CAR T-cell function
Jitendra Kumar et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections
Ekaterina Zmievskaya et al.
BIOMEDICINES (2021)
Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis
Linhui Hu et al.
ANNALS OF HEMATOLOGY (2021)
Transcriptional regulatory network for the establishment of CD8+ T cell exhaustion
Wooseok Seo et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2021)
Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy
Yuqi Zhou et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia (vol 24, pg 563, 2018)
Joseph A. Fraietta et al.
NATURE MEDICINE (2021)
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
Takayoshi Yamauchi et al.
NATURE COMMUNICATIONS (2021)
Synthetic promoters to induce immune-effectors into the tumor microenvironment
Yariv Greenshpan et al.
COMMUNICATIONS BIOLOGY (2021)
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment
Guangna Liu et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19+Raji lymphoma in preclinical models
Brian Webster et al.
MOLECULAR THERAPY (2021)
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
Evan W. Weber et al.
SCIENCE (2021)
CAR-T cell therapy: current limitations and potential strategies
Robert C. Sterner et al.
BLOOD CANCER JOURNAL (2021)
Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells
Laura M. McLane et al.
CELL REPORTS (2021)
TOX as a potential target for immunotherapy in lymphocytic malignancies
Chaofeng Liang et al.
BIOMARKER RESEARCH (2021)
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
Zhenguang Wang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Transforming growth factor-b-regulated mTOR activity preserves cellular metabolism to maintain long-term T cell responses in chronic infection
Sarah S. Gabriel et al.
IMMUNITY (2021)
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin
Nengzhi Pang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma
Xiaoqian Liu et al.
TRANSLATIONAL ONCOLOGY (2021)
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab
Prasad S. Adusumilli et al.
CANCER DISCOVERY (2021)
Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy
Xianhui Chen et al.
MOLECULAR THERAPY-ONCOLYTICS (2021)
Targeting ubiquitin signaling for cancer immunotherapy
Xiaofei Zhou et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Determinants of response and resistance to CAR T cell therapy
Stefanie Lesch et al.
SEMINARS IN CANCER BIOLOGY (2020)
PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges
Eileen McGowan et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity
Haifeng Zhu et al.
PATHOLOGY & ONCOLOGY RESEARCH (2020)
Adoptive T-cell therapy for HBV-associated HCC and HBV infection
Anthony T. Tan et al.
ANTIVIRAL RESEARCH (2020)
Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer
Kyungsoo Kim et al.
GENOME MEDICINE (2020)
Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms
Jean-Christophe Beltra et al.
IMMUNITY (2020)
Charting the Roadmap of T Cell Exhaustion
Talyn Chu et al.
IMMUNITY (2020)
Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review
Laerke J. B. Brandt et al.
FRONTIERS IN IMMUNOLOGY (2020)
Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy
Xiaodong Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
TGFβ suppresses CD8+ T cell expression of CXCR3 and tumor trafficking
Andrew J. Gunderson et al.
NATURE COMMUNICATIONS (2020)
The Role of PD-1 in Acute and Chronic Infection
Jil M. Jubel et al.
FRONTIERS IN IMMUNOLOGY (2020)
Chimeric antigen receptor signaling: Functional consequences and design implications
S. E. Lindner et al.
SCIENCE ADVANCES (2020)
Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer
Tanja Stuber et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma
Zhi-Zhang Yang et al.
CLINICAL CANCER RESEARCH (2020)
CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
Alba Rodriguez-Garcia et al.
FRONTIERS IN IMMUNOLOGY (2020)
Discovery of a novel selective water-soluble SMAD3 inhibitor as an antitumor agent
Nannan Wu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo
Sarah A. Richman et al.
MOLECULAR THERAPY (2020)
A conformation-specific ON-switch for controlling CAR T cells with an orally available drug
Charlotte U. Zajc et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Arming Anti-EGFRvIII CAR-T With TGFβ Trap Improves Antitumor Efficacy in Glioma Mouse Models
You Li et al.
FRONTIERS IN ONCOLOGY (2020)
Adoptive cell therapy: Living drugs against cancer
Tamara Laskowski et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release
Xuan Liu et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors
Na Tang et al.
JCI INSIGHT (2020)
Eomes+T-betlow CD8+ T Cells Are Functionally Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid Leukemia
Bei Jia et al.
CANCER RESEARCH (2019)
Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction
Xindong Liu et al.
NATURE (2019)
NR4A transcription factors limit CAR T cell function in solid tumours
Joyce Chen et al.
NATURE (2019)
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
Laura M. McLane et al.
Annual Review of Immunology (2019)
Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle et al.
IMMUNITY (2019)
CD19 CAR T cell product and disease attributes predict leukemia remission durability
Olivia C. Finney et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Impact of epitope density on CD8+ T cell development and function
Gabriela L. Cosma et al.
MOLECULAR IMMUNOLOGY (2019)
Modulation of chimeric antigen receptor surface expression by a small molecule switch
Alexandre Juillerat et al.
BMC BIOTECHNOLOGY (2019)
TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection
Francesca Alfei et al.
NATURE (2019)
TOX is a critical regulator of tumour-specific T cell differentiation
Andrew C. Scott et al.
NATURE (2019)
TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
Omar Khan et al.
NATURE (2019)
Single-cell RNA-seq reveals TOX as a key regulator of CD8+ T cell persistence in chronic infection
Chen Yao et al.
NATURE IMMUNOLOGY (2019)
TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion
Hyungseok Seo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters
Yong Gu Lee et al.
NATURE COMMUNICATIONS (2019)
CD4+ T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B
Yuejiao Dong et al.
BMC IMMUNOLOGY (2019)
Clinical lessons learned from the first leg of the CAR T cell journey
Robbie G. Majzner et al.
NATURE MEDICINE (2019)
IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+T-lymphocytes in pancreatic cancer
Guoping Ding et al.
BMC CANCER (2019)
TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision
Zeyu Chen et al.
IMMUNITY (2019)
The Transcription Factor Tox2 Drives T Follicular Helper Cell Development via Regulating Chromatin Accessibility
Wei Xu et al.
IMMUNITY (2019)
Beyond the Cell Surface: Targeting Intracellular Negative Regulators to Enhance T cell Anti-Tumor Activity
Poojitha Sitaram et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Regulatory Mechanisms of Inhibitory Immune Checkpoint Receptor Expression
Nicolas Curdy et al.
TRENDS IN CELL BIOLOGY (2019)
CXCR3 enables recruitment and site-specific bystander activation of memory CD8+ T cells
Nicholas J. Maurice et al.
NATURE COMMUNICATIONS (2019)
Adoptive Transfer of Regulatory T Cells as a Promising Immunotherapy for the Treatment of Multiple Sclerosis
Samuel S. Duffy et al.
FRONTIERS IN NEUROSCIENCE (2019)
Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy
Ren-Yu Zhang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection
William H. Hudson et al.
IMMUNITY (2019)
CD4+ T Cell Help Is Required for the Formation of a Cytolytic CD8+ T Cell Subset that Protects against Chronic Infection and Cancer
Ryan Zander et al.
IMMUNITY (2019)
c-Jun overexpression in CAR T cells induces exhaustion resistance
Rachel C. Lynn et al.
NATURE (2019)
Chimeric antigen receptors designed to overcome transforming growth factor-β-mediated repression in the adoptive T-cell therapy of solid tumors
Jordan Hartley et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2019)
Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization
Wai-Hang Leung et al.
JCI INSIGHT (2019)
Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy
Nirali N. Shah et al.
BLOOD ADVANCES (2019)
Blocking IL-2 Signal In Vivo with an IL-2 Antagonist Reduces Tumor Growth through the Control of Regulatory T Cells
Tania Carmenate et al.
JOURNAL OF IMMUNOLOGY (2018)
Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
Christopher C. Kloss et al.
MOLECULAR THERAPY (2018)
Rewiring T-cell responses to soluble factors with chimeric antigen receptors
Zenan L. Chang et al.
NATURE CHEMICAL BIOLOGY (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
Esther Drent et al.
PLOS ONE (2018)
Blockade of Tumor-Expressed PD-1 promotes lung cancer growth
Shisuo Du et al.
ONCOIMMUNOLOGY (2018)
TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
Amina Dahmani et al.
CANCERS (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Tumor Antigen Escape from CAR T-cell Therapy
Robbie G. Majzner et al.
CANCER DISCOVERY (2018)
Development of Inducible CD19-CAR T Cells with a Tet-On System for Controlled Activity and Enhanced Clinical Safety
Xingjian Gu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory
Sophie Viaud et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
Xingliang Guo et al.
FRONTIERS IN PHARMACOLOGY (2018)
High Levels of Eomes Promote Exhaustion of Anti-tumor CD8+ T Cells
Jing Li et al.
FRONTIERS IN IMMUNOLOGY (2018)
T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses
Alireza Saeidi et al.
FRONTIERS IN IMMUNOLOGY (2018)
CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy
Yiyi Yan et al.
JCI INSIGHT (2018)
TGF-β-responsive CAR-T cells promote anti-tumor immune function
Andrew J. Hou et al.
BIOENGINEERING & TRANSLATIONAL MEDICINE (2018)
T Cell-Derived CD70 Delivers an Immune Checkpoint Function in Inflammatory T Cell Responses
Rachel E. O'Neill et al.
JOURNAL OF IMMUNOLOGY (2017)
Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function
Nicholas D. Leigh et al.
JOURNAL OF IMMUNOLOGY (2017)
Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells
Iulia Diaconu et al.
MOLECULAR THERAPY (2017)
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Justin Eyquem et al.
NATURE (2017)
Chromatin states define tumour-specific T cell dysfunction and reprogramming
Mary Philip et al.
NATURE (2017)
Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models
Melinda Mata et al.
CANCER DISCOVERY (2017)
Cblb-deficient T cells are less susceptible to PD-L1-mediated inhibition
Sebastian Peer et al.
ONCOTARGET (2017)
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
Levi J. Rupp et al.
SCIENTIFIC REPORTS (2017)
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
Oladapo O. Yeku et al.
SCIENTIFIC REPORTS (2017)
Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation
Mai Fujiwara et al.
FRONTIERS IN IMMUNOLOGY (2017)
Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
Inna Serganova et al.
MOLECULAR THERAPY-ONCOLYTICS (2017)
Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy
Miren Zuazo et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors
Si Li et al.
CLINICAL CANCER RESEARCH (2017)
T cell exhaustion: from pathophysiological basics to tumor immunotherapy
Kemal Catakovic et al.
CELL COMMUNICATION AND SIGNALING (2017)
Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy
Oladapo O. Yeku et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2016)
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
Benjamin V. Park et al.
CANCER DISCOVERY (2016)
The PD1:PD-L1/2 Pathway from Discovery to Clinical implementation
Kankana Bardhan et al.
FRONTIERS IN IMMUNOLOGY (2016)
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation
Xiaoou Zhou et al.
BLOOD (2015)
Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
Chia-Yung Wu et al.
SCIENCE (2015)
Overcoming T cell exhaustion in infection and cancer
Kristen E. Pauken et al.
TRENDS IN IMMUNOLOGY (2015)
Modulation of immune cell functions by the E3 ligase Cbl-b
Christina Lutz-Nicoladoni et al.
FRONTIERS IN ONCOLOGY (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma
Z-Z Yang et al.
LEUKEMIA (2014)
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
Liza B. John et al.
CLINICAL CANCER RESEARCH (2013)
Clonal exhaustion as a mechanism to protect against severe immunopathology and death from an overwhelming CD8T cell response
Markus Cornberg et al.
FRONTIERS IN IMMUNOLOGY (2013)
Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation
Nikolaos Patsoukis et al.
SCIENCE SIGNALING (2012)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
Chrystal U. Louis et al.
BLOOD (2011)
Increased sensitivity to antigen in high avidity CD8+T cells results from augmented membrane proximal T-cell receptor signal transduction
Sharad K. Sharma et al.
IMMUNOLOGY (2011)
TOX Is Required for Development of the CD4 T Cell Lineage Gene Program
Parinaz Aliahmad et al.
JOURNAL OF IMMUNOLOGY (2011)
Memory CD8(+) T cell differentiation
Joshua J. Obar et al.
YEAR IN IMMUNOLOGY 2 (2010)
One naive T cell, multiple fates in CD8+ T cell differentiation
Carmen Gerlach et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery
Shaobo Han et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Chronic Antigen Stimulation Alone Is Sufficient to Drive CD8+ T Cell Exhaustion
Christine M. Bucks et al.
JOURNAL OF IMMUNOLOGY (2009)
Cutting edize: Dendritic cells prime a high avidity CTL response independent of the level of presented antigen
Charles J. Kroger et al.
JOURNAL OF IMMUNOLOGY (2008)
Cutting edge:: CD8+ T cell clones possess the potential to differentiate into both high- and low-avidity effector cells
Charles J. Kroger et al.
JOURNAL OF IMMUNOLOGY (2007)
Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells
Stefanie Loeser et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Ablation of Cbl-b provides protection against transplanted and spontaneous tumors
Jeffrey Y. Chiang et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells
Yuanyuan Zha et al.
CELLULAR IMMUNOLOGY (2007)
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
DA Thomas et al.
CANCER CELL (2005)
TGF-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells
M Ahmadzadeh et al.
JOURNAL OF IMMUNOLOGY (2005)
Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction
MS Jeon et al.
IMMUNITY (2004)
SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo
M Uhl et al.
CANCER RESEARCH (2004)
Cbl-b regulates the CD28 dependence of T-cell activation
YPJ Chiang et al.
NATURE (2000)